The $300,000 Difference: Managing the Cost of Specialty Drugs

The $300,000 Difference: Managing the Cost of Specialty Drugs. It often starts with a diagnosis. An employee receives news that changes everything. It might be breast cancer, multiple sclerosis, rheumatoid arthritis, or another condition that requires advanced treatment.

Their physician may recommend a specialty therapy – targeted medication designed to treat complex diseases more effectively than traditional therapies. For the patient, this can be hopeful news. These treatments are often life-saving and can dramatically improve outcomes.

But behind the scenes, there is another reality emerging. Many of these breakthrough therapies come with extremely high costs. For employer-sponsored health plans – particularly self-funded plans – a single specialty therapy can quickly become one of the largest claims in the entire plan.

And in many cases, the total cost has less to do with the medication itself and more to do with how the drug is sourced, billed, and administered.

Understanding J-Code and Q-Code medications

J-codes and Q-codes are used to bill medications that are administered by a healthcare provider rather than filled at a pharmacy. These therapies are typically delivered through infusion or injection during a clinical visit and are commonly used to treat complex and chronic conditions such as cancer, multiple sclerosis, rheumatoid arthritis, multiple myeloma, and other autoimmune disorders.

Unlike medications filled through a traditional pharmacy benefit, these drugs are typically purchased by the healthcare facility providing the treatment. The facility then bills the employer’s health plan for both the medication and the administration of the infusion during the patient’s visit.

This billing structure creates a major variable in healthcare costs. The exact same medication can be billed at dramatically different prices depending on where the infusion takes place and how the drug is sourced.

Why infusion claims can escalate quickly.

Hospitals and infusion centers typically acquire specialty medications and bill the health plan using formulas tied to the drug’s Average Wholesale Price (AWP). Once facility markups and administration fees are added, it is not uncommon to see infused medications billed at two to three times the wholesale cost of the drug itself.

Because many of these therapies are administered on a recurring schedule, the financial impact compounds quickly over time. A single patient receiving infused specialty medications can generate hundreds of thousands of dollars in annual claims within an employer health plan.

What this looks like in practice.

Consider a patient undergoing treatment for HER2-positive breast cancer who receives the following medications every three weeks:

• J9306 – Perjeta
• Q5117 – Kanjinti
• J2506 – Neulasta

Under a traditional hospital infusion model, the total cost billed to the employer health plan for a single treatment cycle was $50,703.

However, when the medications were sourced differently and administered outside the traditional hospital billing structure, the cost was reduced to $31,536 per treatment. Over the course of 17 treatment cycles per year, the difference becomes substantial.

• Using traditional facility billing, the total annual cost reached $861,951.
• With an alternative drug sourcing strategy, the annual cost dropped to $536,112.

This means that for a single patient, the employer saved $325,839 annually, all without changing the prescribed therapy – the savings came entirely from how the medication was sourced and the infusion was delivered.

Why this matters for self-funded employers

For employers with self-funded health plans, specialty infusion claims don’t just affect the current year’s healthcare spending. They can also influence future plan stability and stop-loss coverage.

Many employer-sponsored plans operate with stop-loss deductibles between $150,000 and $250,000 per claimant. When specialty drug claims climb well beyond those thresholds, employers may experience higher stop-loss renewals, claimant-specific lasers, and increased long-term plan costs.

When you can reduce the cost of a high-value therapy by hundreds of thousands of dollars, it doesn’t just affect one patient’s claim; it can change the outlook of the entire health plan.

Managing specialty drug costs is not about restricting access to care.

These therapies are often life-saving and essential for many serious conditions. The opportunity for employers is in ensuring those treatments are delivered through the most clinically appropriate and financially responsible model available.

Increasingly, employers and their advisors are exploring several strategies to better 

manage these claims:

• Site-of-care optimization: Evaluating whether hospital-based infusions are necessary or whether treatment can occur in lower-cost clinical settings.
• Alternative drug sourcing: Purchasing specialty medications through specialty pharmacies rather than allowing facilities to apply significant markups.
• Single-case agreements (SCAs): Negotiating case-specific pricing with providers for high-cost therapies.
• Medical-to-pharmacy benefit strategies: Transitioning certain medications to the pharmacy benefit where pricing transparency may be greater.

These approaches focus on reducing unnecessary markups and ensuring employees continue to receive the treatment they need.

Specialty medications are among the fastest-growing drivers of healthcare spending today.

As more therapies receive approval, both utilization and costs for employer-sponsored health plans are rising. In fact, the IQVIA Institute, projects that specialty medications will account for about 43% of global drug spending by 2028, a trend that is already putting pressure on U.S. employers’ health plans.

For employers focused on building long-term stability within their health plans, evaluating how specialty infusion therapies are sourced, billed, and administered is quickly becoming one of the most important healthcare cost conversations to have. 

Because when that life-changing diagnosis happens, the goal should always be the same: ensure the patient receives the best care possible while the health plan pays a fair and sustainable price for it.

If you want to discuss specialty medications or have questions about your benefits program, don’t wait; reach out today!

Cost figures, coverage details, and plan design elements presented in this blog are for illustrative purposes only and do not reflect any specific insurance policy or provider. Actual costs will vary based on your organization’s health plan, the insurance carrier, provider contracts, and the specifics of each medical situation. Employers and employees should refer to their official plan documents or speak with their broker or benefits consultant for guidance if needed.